Pioglitazone, a close PPARγ agonist to Rosiglitazone, is currently undergoing clinical trials for ADPKD [ClinicalTrials.gov Identifier: NCT02697617]. This evidence concerns the gene PPARG and autosomal dominant polycystic kidney disease.